156 related articles for article (PubMed ID: 29153415)
1. Comparison of the rapid effects of single inhalations of formoterol and tiotropium bromide on respiratory function and COPD symptoms in a randomized crossover study.
Ohbayashi H
Respir Investig; 2017 Nov; 55(6):348-356. PubMed ID: 29153415
[TBL] [Abstract][Full Text] [Related]
2. Effects of indacaterol versus tiotropium on respiratory mechanics assessed by the forced oscillation technique in patients with chronic obstructive pulmonary disease.
Inui N; Matsushima S; Kato S; Yasui H; Kono M; Fujisawa T; Enomoto N; Nakamura Y; Toyoshima M; Suda T
Int J Chron Obstruct Pulmon Dis; 2015; 10():1139-46. PubMed ID: 26124653
[TBL] [Abstract][Full Text] [Related]
3. Early bronchodilator action of glycopyrronium versus tiotropium in moderate-to-severe COPD patients: a cross-over blinded randomized study (Symptoms and Pulmonary function in the moRnING).
Marin JM; Beeh KM; Clemens A; Castellani W; Schaper L; Saralaya D; Gunstone A; Casamor R; Kostikas K; Aalamian-Mattheis M
Int J Chron Obstruct Pulmon Dis; 2016; 11():1425-34. PubMed ID: 27418815
[TBL] [Abstract][Full Text] [Related]
4. Bronchodilator efficacy of tiotropium/formoterol (18/12 µg once daily via a Discair inhaler), tiotropium alone (18 µg by Handihaler) or combined with formoterol (12 µg twice daily by Aerolizer) in adults with moderate-to-severe stable COPD.
Yildiz BP; Bayraktaroglu M; Gunen H
Curr Med Res Opin; 2019 Dec; 35(12):2187-2196. PubMed ID: 31397184
[No Abstract] [Full Text] [Related]
5. AMPLIFY: a randomized, Phase III study evaluating the efficacy and safety of aclidinium/formoterol vs monocomponents and tiotropium in patients with moderate-to-very severe symptomatic COPD.
Sethi S; Kerwin E; Watz H; Ferguson GT; Mroz RM; Segarra R; Molins E; Jarreta D; Garcia Gil E
Int J Chron Obstruct Pulmon Dis; 2019; 14():667-682. PubMed ID: 30962681
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of fixed-dose combinations of aclidinium bromide/formoterol fumarate: the 24-week, randomized, placebo-controlled AUGMENT COPD study.
D'Urzo AD; Rennard SI; Kerwin EM; Mergel V; Leselbaum AR; Caracta CF;
Respir Res; 2014 Oct; 15(1):123. PubMed ID: 25756831
[TBL] [Abstract][Full Text] [Related]
7. Single inhaler extrafine triple therapy versus long-acting muscarinic antagonist therapy for chronic obstructive pulmonary disease (TRINITY): a double-blind, parallel group, randomised controlled trial.
Vestbo J; Papi A; Corradi M; Blazhko V; Montagna I; Francisco C; Cohuet G; Vezzoli S; Scuri M; Singh D
Lancet; 2017 May; 389(10082):1919-1929. PubMed ID: 28385353
[TBL] [Abstract][Full Text] [Related]
8. A Single Institution Retrospective Study of the Clinical Efficacy of Tiotropium Respimat in Never-Smoking Elderly Asthmatics with Irreversible Airflow Limitation.
Hara J; Kasahara K; Ohkura N; Yamamura K; Sakai T; Abo M; Ogawa N; Saeki K; Koba H; Watanabe S; Uchida Y; Tambo Y; Sone T; Kimura H
Drug Res (Stuttg); 2019 Apr; 69(4):211-217. PubMed ID: 30193393
[TBL] [Abstract][Full Text] [Related]
9. Effects of inhaled tiotropium plus transdermal tulobuterol versus tiotropium alone on impulse oscillation system (IOS)-assessed measures of peripheral airway resistance and reactance, lung function and quality of life in patients with COPD: a randomized crossover study.
Abe T; Setoguchi Y; Kono Y; Togashi Y; Sugiyama S; Tanakadate M; Soeda S; Nakai M; Sugiyama N; Fujiwara A; Yamaguchi K; Yamaguchi A; Kurita N
Pulm Pharmacol Ther; 2011 Oct; 24(5):617-24. PubMed ID: 21689775
[TBL] [Abstract][Full Text] [Related]
10. Umeclidinium/vilanterol as step-up therapy from tiotropium in patients with moderate COPD: a randomized, parallel-group, 12-week study.
Kerwin EM; Kalberg CJ; Galkin DV; Zhu CQ; Church A; Riley JH; Fahy WA
Int J Chron Obstruct Pulmon Dis; 2017; 12():745-755. PubMed ID: 28280319
[TBL] [Abstract][Full Text] [Related]
11. A multicenter, randomized, double-blind dose-ranging study of glycopyrrolate/formoterol fumarate fixed-dose combination metered dose inhaler compared to the monocomponents and open-label tiotropium dry powder inhaler in patients with moderate-to-severe COPD.
Tashkin DP; Martinez FJ; Rodriguez-Roisin R; Fogarty C; Gotfried M; Denenberg M; Gottschlich G; Donohue JF; Orevillo C; Darken P; St Rose E; Strom S; Fischer T; Golden M; Reisner C
Respir Med; 2016 Nov; 120():16-24. PubMed ID: 27817811
[TBL] [Abstract][Full Text] [Related]
12. Effects of Adding Tiotropium or Aclidinium as Triple Therapy Using Impulse Oscillometry in COPD.
Manoharan A; Morrison AE; Lipworth BJ
Lung; 2016 Apr; 194(2):259-66. PubMed ID: 26758884
[TBL] [Abstract][Full Text] [Related]
13. The Tiotropium Safety and Performance in Respimat® (TIOSPIR®) Trial: Spirometry Outcomes.
Anzueto A; Wise R; Calverley P; Dusser D; Tang W; Metzdorf N; Dahl R
Respir Res; 2015 Sep; 16(1):107. PubMed ID: 26369563
[TBL] [Abstract][Full Text] [Related]
14. Tiotropium HandiHaler(®) and Respimat(®) in COPD: a pooled safety analysis.
Halpin DM; Dahl R; Hallmann C; Mueller A; Tashkin D
Int J Chron Obstruct Pulmon Dis; 2015; 10():239-59. PubMed ID: 25709423
[TBL] [Abstract][Full Text] [Related]
15. Bronchodilator Effect of Tiotropium via Respimat
Ogasawara T; Sakata J; Aoshima Y; Tanaka K; Yano T; Kasamatsu N
Intern Med; 2017 Sep; 56(18):2401-2406. PubMed ID: 28824055
[TBL] [Abstract][Full Text] [Related]
16. Characteristics of COPD patients initiating treatment with aclidinium or tiotropium in primary care in Catalonia: a population-based study.
Monteagudo M; Roset M; Rodriguez-Blanco T; Muñoz L; Miravitlles M
Int J Chron Obstruct Pulmon Dis; 2017; 12():1145-1152. PubMed ID: 28442901
[TBL] [Abstract][Full Text] [Related]
17. Tiotropium in chronic obstructive pulmonary disease - a review of clinical development.
Anzueto A; Miravitlles M
Respir Res; 2020 Jul; 21(1):199. PubMed ID: 32727455
[TBL] [Abstract][Full Text] [Related]
18. Concomitant treatment with nebulized formoterol and tiotropium in subjects with COPD: a placebo-controlled trial.
Tashkin DP; Littner M; Andrews CP; Tomlinson L; Rinehart M; Denis-Mize K
Respir Med; 2008 Apr; 102(4):479-87. PubMed ID: 18258423
[TBL] [Abstract][Full Text] [Related]
19. Pharmacological assessment of the onset of action of aclidinium and glycopyrronium versus tiotropium in COPD patients and human isolated bronchi.
Rogliani P; Calzetta L; Ora J; Lipsi R; Segreti A; Matera MG; Cazzola M
Eur J Pharmacol; 2015 Aug; 761():383-90. PubMed ID: 25952728
[TBL] [Abstract][Full Text] [Related]
20. Consistent improvement in health-related quality of life with tiotropium in patients with chronic obstructive pulmonary disease: Novel and conventional responder analyses.
Tashkin DP; Bateman ED; Jones P; Zubek VB; Metzdorf N; Liu D; Leonard T; Clerisme-Beaty E; Wise RA
Respir Med; 2016 Nov; 120():91-100. PubMed ID: 27817821
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
